Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
about
Virtual karyotyping with SNP microarrays reduces uncertainty in the diagnosis of renal epithelial tumorsCombining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cellsSafety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesTargeted therapy for advanced renal cell carcinomaSPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancerPericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expressionA comprehensive overview of targeted therapy in metastatic renal cell carcinomamTOR inhibitors in advanced renal cell carcinomaAxitinib for the management of metastatic renal cell carcinomaAccurate molecular classification of renal tumors using microRNA expressionState of the science: an update on renal cell carcinomaHistological reclassification, histochemical characterization and c-kit immunoexpression in renal cell carcinomaImmunobiology and immunotherapy in genitourinary malignanciesContemporary Treatment of Metastatic Renal Cell CarcinomaReview of renal cell carcinoma and its common subtypes in radiologySaudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinomaThyroid Hormones as Renal Cell Cancer RegulatorsRecent developments in receptor tyrosine kinases targeted anticancer therapyAxitinib in the treatment of renal cell carcinoma: patient selection and perspectivesHeritable Cancer Syndromes Related to the Hypoxia PathwayBeyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaChinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinomaCytoreductive surgery in the era of targeted molecular therapyProfile of nintedanib in the treatment of solid tumors: the evidence to dateTargeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinomaRemodeling Components of the Tumor Microenvironment to Enhance Cancer TherapyWithdrawal of anticancer therapy in advanced disease: a systematic literature reviewMolecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicineThe Emerging Regulation of VEGFR-2 in Triple-Negative Breast CancerMore than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsCytoreductive nephrectomy and its role in the present-day period of targeted therapy.Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analysesManagement of inferior vena cava tumor thrombus in locally advanced renal cell carcinomaTherapeutic challenges in renal cell carcinomaContemporary approaches for imaging skeletal metastasisRenal cell carcinoma: histological classification and correlation with imaging findingsCombining radiotherapy with sunitinib: lessons (to be) learnedMultidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvementRisk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials
P2860
Q21203678-BCD84B66-CA91-4DFD-9456-DD699C7C4832Q21260390-CA77B26D-0D20-41D3-9920-0C83B9327E00Q21261307-6D23FA05-3FF6-4C70-AF85-25A54C90B5E9Q24242946-85FFFE1C-E6E7-4C74-9400-9BE991F412B7Q24339492-914C2470-E1D9-40EB-8AB8-C99FEA696855Q24595357-E3789B0C-7BEC-4E6B-A31E-D4B51C5A73AAQ24606852-F2BE4517-B3E2-44FD-8063-3F69C3188FADQ24612127-2671FC38-5F78-4692-9E58-C29D313A9219Q24613720-E52D4FB1-88B4-407D-8F7C-A153C49ADDDBQ24625843-62CB4304-1427-408D-8C15-0A7F99F16B6EQ24630685-B818FF46-9AEB-4AEB-A17C-4CB29ADD324DQ24658263-010EA870-06AA-47CD-9DE7-5F6FD6482A56Q26738668-76EDC4FB-F1CB-4CAE-AAAB-1DA025FAD54BQ26740594-BB61F503-0FB4-4FC4-B569-A8CE510F0C11Q26744297-5AD20FC8-767D-43A5-A7F9-B8C26653D368Q26747767-B4ED2CF7-AEB6-419C-8449-C40C5595EC43Q26748991-926D2443-E0FD-4C0B-8FD6-330986BEE067Q26751331-B198DC90-4C93-460C-ADAE-3DEA3A52B7F6Q26751341-F2739566-AB4F-4BCA-A3A2-18CD1A5E12CAQ26751590-C85FC7B8-28FF-4B81-841F-418BBE5EFEDBQ26766240-B5A27547-9E28-465B-AE29-79A4C6BFC6E1Q26772206-051A7F1F-3229-4F23-AE36-42C02F72E58AQ26773653-34B99C7C-0934-4C92-AFFD-31AEFBBD0E5AQ26774134-934C526C-71D4-47A7-9B11-4F716FC3E4B6Q26775134-2841167F-7856-4BCD-8975-B07DE51D9B5AQ26775769-53295648-090A-4B33-BF37-9C03879893BAQ26777144-B15CF275-8A17-4D14-B062-0D152E4735E2Q26777486-E5BEDA1E-CF15-4C2B-A0E3-8CB05C0BDCA9Q26779144-97C319B2-E579-429C-AA4C-B4D13A446FE0Q26779248-68CA0149-9A5F-4732-A1FD-5C3C4E320686Q26781662-C78D6642-4FB9-41D2-9CE3-C61C8C4A8004Q26783520-73D14439-99FC-4037-8215-78B55CAA95B4Q26786243-F9BBC34B-ABDA-465B-A9D4-B5DB9DE770A7Q26786534-FE0DF49A-7ADF-49D9-9415-3F9E6C3274F8Q26796702-96197FDF-E447-41ED-ABA4-D1AF8C5E479BQ26798170-FA35A132-C481-44BF-9168-B9B87A7194C8Q26799781-174B91CB-B2BD-467D-A965-3EDB04F7017BQ26800587-F9C86BDD-4EAA-4449-8340-2B3F7069A61BQ26801279-6EB8EBCC-77E9-4389-AD0A-7ECC509579C8Q26822790-47C71AFE-6722-4E00-AFFE-1EB8894F590D
P2860
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
@ast
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
@en
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
@nl
type
label
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
@ast
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
@en
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
@nl
prefLabel
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
@ast
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
@en
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
@nl
P2093
P3181
P356
P1476
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
@en
P2093
Cezary Szczylik
Charles M Baum
M Dror Michaelson
Paul W Bycott
Piotr Tomczak
Robert A Figlin
Ronald M Bukowski
Sindy T Kim
Stéphane Oudard
P304
P3181
P356
10.1056/NEJMOA065044
P407
P577
2007-01-11T00:00:00Z